罗氏/基因泰克预告ESMO 2026将公布divarasib、giredestrant及Tam-Peli数据，无新增定量结果

Genentech, a member of the Roche Group (RHHBY), announced that it will present new data from the Phase III Krascendo 1 trial evaluating divarasib in previously treated advanced G12C-mutated non-small cell lung cancer and patient-reported outcomes from the Phase III lidERA study evaluating giredestrant in early-stage breast cancer at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting, held from 23 to 27 October in Madrid.
The presentations also include two late-breaking abstracts across lung, breast and other cancers.
Divarasib Highlights
Krascendo 1 is a global head-to-head trial evaluating divarasib, an investigational KRAS G12C inhibitor, against approved first-generation inhibitors.
According to the company, phase III Krascendo 1 results demonstrated divarasib's superiority over the current standard of care, first-generation KRAS G12C inhibitors, in previously treated advanced G12C-mutated non-small cell lung cancer.
Giredestrant Highlights
Giredestrant is an investigational, oral, selective estrogen receptor degrader (SERD) and full antagonist in estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, a subtype in which more than 90% of cases are diagnosed at an early stage (I-III).
According to the company, patient-reported outcomes from the Phase III lidERA study showed that giredestrant improved efficacy over standard endocrine therapy without compromising tolerability or health-related quality of life in early-stage breast cancer.
The data will also include,
- Exploratory biomarker findings from the evERA Breast Cancer trial of giredestrant in combination with everolimus in ER-positive, HER2-negative advanced breast cancer in the post-cyclin-dependent kinase 4/6 inhibitor setting.
- Updated interim results for giredestrant plus inavolisib from the MORPHEUS Breast Cancer trial evaluating giredestrant treatment combinations in ER-positive, HER2-negative locally advanced or metastatic breast cancer.
Tam-Peli Highlights
In addition, the company said additional Phase 3 results in Chinese patients with metastatic nasopharyngeal carcinoma showed that Tam-Peli, a B7-H3 targeted antibody-drug conjugate (ADC), demonstrated efficacy and a favourable safety profile.
For Tam-Peli, data include late-breaking interim Phase 3 results in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma, analyses of interstitial lung disease in patients with advanced solid tumours from Phase I/II studies, and Phase I efficacy and safety data for Tam-Peli in patients with locally advanced or metastatic NSCLC.
The company said the new findings reinforce positive Phase 3 TAISHAN-302 results, which previously met key endpoints of overall survival, progression-free survival, and objective response rate in second-line small cell lung cancer.
Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong, and Macau, and plans to initiate global trials across multiple tumour types.
Stock Performance
RHHBY has traded between $301.27 and $514.08 over the last year. The stock closed Friday's trade at $458.47.
For more such biotech stock news, visit www.rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.